Commentary

Podcast

Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions

Author(s):

Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by AstraZeneca, we had the pleasure of speaking with Jessica S. Donington, MD, MSCR, and Brendon M. Stiles, MD, about surgical perspectives on key lung cancer treatment developments. Dr Donington is a professor of surgery and chief of the Section of Thoracic Surgery in the Department of Surgery at the University of Chicago in Illinois. Dr Stiles is chief of Thoracic Surgery and Surgical Oncology, as well as the associate director of Surgical Oncology at Montefiore Einstein Comprehensive Cancer Center in the Bronx, New York, where he is also a professor in the Department of Cardiothoracic & Vascular Surgery, a professor in the Department of Oncology (Medical Oncology), and a professor in the Department of Medicine (Oncology & Hematology).

In part 1 of our exclusive 2-part interview, Drs Donington and Stiles discussed how the findings from the phase 3 ADAURA trial (NCT02511106) with adjuvant osimertinib (Tagrisso) have changed thoracic surgery expectations, the potential surgical implications of the phase 3 ALINA trial (NCT03456076) with adjuvant alectinib (Alecensa), and the importance of early-stage molecular testing in lung cancer.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by AstraZeneca. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Sheldon M. Feldman, MD
Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.
Saad J. Kenderian, MB, CHB
Neel P. Chudgar, MD
Balazs Halmos, MD
Beth N. McLellan, MD, director, supportive oncodermatology, Montefiore Einstein Cancer Center, chief, Division of Dermatology, Montefiore Health System, Albert Einstein College of Medicine
Experts on lung cancer
Expert on lung cancer
Expert on lung cancer
Expert on lung cancer